These stocks look like slam-dunk picks for growth investors.October sometimes gets a bad rap from investors. Sure, several major stock market crashes have occurred during the month in the past. However, October has actually been a pretty good month for stocks historically. Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they picked Eli Lilly (LLY 2.35%), Novo Nordisk (NVO 2.14%), and Vertex Pharmaceuticals (VRTX 1.17%).A plethora of gr ...

Eli Lilly and Company TodayLLYEli Lilly and Company$932.06 +21.37 (+2.35%) 52-Week Range$547.61▼$972.53Dividend Yield0.56%P/E Ratio114.79Price Target$979.29Add to WatchlistIn a year and a half, Eli Lilly NYSE: LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson NYSE: JNJ back in May of 2023 and hasn’t looked back since. However, much of that increase in value has come due to multiple expans ...

The latest trading session saw Eli Lilly (LLY) ending at $910.69, denoting a -0.98% adjustment from its last day's close. This move lagged the S&P 500's daily loss of 0.21%. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, lost 0.05%.Shares of the drugmaker witnessed a loss of 0.12% over the previous month, beating the performance of the Medical sector with its loss of 3.28% and underperforming the S&P 500's gain of 5.94%.The upcoming earnings release of Eli Lilly will be of great interest ...

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.Dividend-paying stocks have been dominant performers in the U.S. market since 1900. Their power lies in compounding, which can substantially increase returns over time.Companies that consistently raise their dividends frequently outperform the S&P 500 over long periods. These dividend growers often feature strong fundamentals, proven business models, and management teams focused on shareholder ret ...

Eli Lilly's (LLY, Financial) stock experienced a notable movement, rising 1.71% to a price of $913.72. This surge was driven by the Congressional Budget Office (CBO) report on the potential impact if Medicare were to cover anti-obesity medications, including Eli Lilly's weight loss drug, Zepbound.The CBO estimates this Medicare coverage could increase federal spending by $35 billion from 2026 to 2034, underscoring the significant sales potential for GLP-1 drugs in the weight loss market. Investors have resp ...

The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.Most investors are aware of the vast sales potential for the effective new weight loss treatments known as GLP-1 drugs, and the market for them is still relatively quite young. On Tuesday, the Congressional Budget Office (CBO) put a number on one piece of that market's potential. As that figure was large, weight loss drug producer Eli Lilly (LLY 1.70%) saw a nearly 2% bump in its share price in response. That compa ...

 SAN CARLOS, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Qinotto, Inc., a central nervous system (CNS) focused biopharmaceutical company that is discovering novel vehicles to deliver large molecule therapeutics to the brain, announced today that it has entered a research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover next-generation antibody-based vehicles for brain transport. Under this collaboration agreement, Qinotto will partner with Lilly Catalyze360-ExploR&D (https:// ...

文章核心观点 - 美国食品药品监督管理局(FDA)决定将艾利·莱利(Eli Lilly)的减肥药从短缺药品清单中移除,引发了制药外包协会的诉讼 [1] - 制药外包协会认为FDA的决定是"任意的、武断的和非法的",限制了患者获取关键药物的途径 [1][2] - FDA认为艾利·莱利的药品短缺问题已得到解决,但制药外包协会认为短缺问题并未真正结束 [1][2] 行业总结 - 艾利·莱利正在采取措施改善药品供应,包括在印第安纳州建立新的生产设施 [2] - 一些制药外包公司可能会继续根据联邦规定生产该药品,以满足特定患者的需求 [2] - 这起诉讼突出了药品短缺对患者获取药物的影响,并引发了人们对FDA决策过程的透明度和合理性的担忧 [2] - 患者可能面临更高的药品费用或需要寻找替代治疗方案 [2]

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.Eli Lilly (LLY 1.27%) stock has climbed in the double digits over the past year thanks to its leading position in one of the highest-growth pharmaceutical markets around: weight loss drugs. Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight control. Doctors have prescribed both for the weight loss indication though, and demand has been so high that it' ...

The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and Eli Lilly (LLY) have witnessed tremendous success, which has played a key role in the industry’s outperformance.  Large drugmakers have several robust revenue streams and are mostly profitable companies, which makes them safe havens for investments. Innovation is key to the growth of the industry. Innovation ...